BlackRock, Inc. 13D and 13G filings for Zevra Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 4,080,420 7.600% | 1,670,131 (+69.29%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 2,410,289 5.800% | 1,557,440 (+182.62%) | Filing |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 852,849 2.500% | -1,382,693 (-61.85%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Zevra Therapeutics, Inc. ZVRA | BlackRock Inc. BLK | 2,235,542 6.300% | 2,235,542 (New Position) | Filing |